Breakthrough Technologies in Cell and Viral Therapies

BPI West: Day 1 Recap

“The future disruption of therapeutic modalities is closer than we think.” – Uwe Gottschalk

In Track 3, Late Stage Process Development & Commercial Launch Preparation, for a standing room only crowd, the featured presentation was given by Uwe Gottschalk, Chief Scientific Officer at Lonza. This track was developed to help attendees learn best practices to apply new technologies used by industry leaders to mitigate risk, improve product quality and ensure regulatory compliance for promising biologics. This exciting presentation included discussions around; T-Cell based cancer treatments, an overview of allo vs. auto, the challenges in scaling of products, the need for automation, disruptive technology and much more.

Continue reading “Breakthrough Technologies in Cell and Viral Therapies”

Working Towards the Ultimate Endpoint of Commercial Manufacturing

At BioProcess International Conference & Exposition West in Oakland, CA, we sat down with Paul Wu, Ph.D., the Director of Upstream Development, Global Biological Development, and Global Biologics at Bayer Pharmaceuticals. Dr. Wu also presented new data on “Finding Synergy: Co-location with Commercial Manufacturing for Process Development” at the event. In the interview, we asked Paul how Bayer are addressing changes in the new regulatory and compliance environment and the setup of Bayer’s development teams.

Continue reading “Working Towards the Ultimate Endpoint of Commercial Manufacturing”